08 April 2026 : Clinical Research
Efficacy and Safety of Liposomal Bupivacaine in Direct Anterior Approach Total Hip Arthroplasty: A Retrospective Cohort Study
Ye Chen
ABCDEF 1, Chunxiao Zhang AD 2, Lanyong Chen B 1, Yong He B 1, Linling Zhang B 1, Songfeng Hu AG 1,2*
DOI: 10.12659/MSM.951717
Med Sci Monit 2026; 32:e951717
Table 5 Comparison of liver and kidney function indicators between the liposomal bupivacaine (LB) and ropivacaine groups.
| Item | LB group (n=61) | Ropivacaine group (n=68) | P value |
|---|---|---|---|
| ALT (U/L) | |||
| Before treatment | 22.05±15.17 | 19.78±11.29 | 0.321 |
| After treatment | 23.04±13.54 | 22.86±12.69 | 0.929 |
| AST (U/L) | |||
| Before treatment | 22.69±10.59 | 22.07±9.17 | 0.619 |
| After treatment | 26.61±9.41 | 27.86±9.77 | 0.252 |
| SCR (μmol/L) | |||
| Before treatment | 64.23±17.19 | 65.69±22.86 | 0.904 |
| After treatment | 62.63±14.05 | 64.75±21.57 | 0.899 |
| Complications [case (%)] | |||
| Nausea and vomiting | 3 (4.92) | 12 (17.65) | 0.024 |
| Significant blood glucose fluctuation | 1 (1.64) | 4 (5.88) | 0.369 |
| Lower extremity intramuscular venous thrombosis | 10 (16.39) | 7 (10.24) | 0.307 |
| Constipation | 6 (9.84) | 11 (16.18) | 0.288 |
| Data are presented as mean±SD or number of patients (%). ALT – alanine aminotransferase; AST – aspartate aminotransferase; SCR – serum creatinine. | |||